ArticleNPJ breast cancer2022

Estrogen receptor beta repurposes EZH2 to suppress oncogenic NFκB/p65 signaling in triple negative breast cancer.

Kirsten G M Aspros et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.